MEDEZE Group Offers IPO Filing for 150 Million Shares


MEDEZE Group, a pioneering company in stem cell and immune cell innovation, has submitted an IPO filing to the Office of SEC. The company plans to offer nearly 150 million shares, which will be listed on the Stock Exchange of Thailand.

The capital raised from this initiative will position MEDEZE as the leading biotech company in Asia.

Dr. Veerapol Khemarangsan, Chief Executive Officer of MEDEZE Group Public Company Limited (“Company” or MEDEZE), shared that the company specialises in providing services for stem cell analysis, isolation, cultivation, and storage, as well as examining the potential of immune cells (NK Cells). MEDEZE has been successfully operating for over 13 years, offering long-term stem cell storage with innovative and cutting-edge technology. The company’s…

Read more…

See also  Last resorts? Phuket and Bali chase dream of COVID-free tourism